



## **Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2019 Financial Results on November 12, 2019**

September 17, 2019

CANTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2019 financial results will be reported after the market closes on Tuesday, November 12.

Management will host a conference call at 5:00 p.m. Eastern Time on November 12 to discuss the results of the quarter and provide a corporate update with a question and answer session. Those who would like to participate may dial 866-795-3142 (409-937-8908 for international callers) and provide access code 4658443. A live webcast of the call will also be provided on the investor relations section of the Company's website at [investors.organogenesis.com](http://investors.organogenesis.com).

For those unable to participate, a replay of the call will be available for two weeks at 855-859-2056 (404-537-3406 for international callers); access code 4658443. The webcast will be archived at [investors.organogenesis.com](http://investors.organogenesis.com).

### **About Organogenesis Holdings Inc.**

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis's comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit [www.organogenesis.com](http://www.organogenesis.com).

### **Investor Inquiries:**

Westwicke PartnersMike Piccinino, CFA

[OrganoIR@westwicke.com](mailto:OrganoIR@westwicke.com)

443-213-0500

### **Press and Media Inquiries:**

OrganogenesisAngelyn Lowe[alowe@organo.com](mailto:alowe@organo.com)

781-774-9364



Source: Organogenesis Holdings Inc.